Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904237193> ?p ?o ?g. }
- W2904237193 endingPage "453" @default.
- W2904237193 startingPage "433" @default.
- W2904237193 abstract "Idiopathic pulmonary fibrosis (IPF), the most common and lethal of all chronic idiopathic interstitial pneumonias, is a disease that is rare and is still regarded as an orphan condition. Indeed, in the last decade more than 3000 patients have been enrolled in high-quality clinical trials of IPF, an impressive achievement for a rare condition. The most challenging obstacle in clinical trials of orphan drugs is the recruitment of an adequate number of patients to obtain sufficient evidence of efficacy and safety. Similarly critical, if not more so, is the choice of the appropriate primary endpoint(s). In disorders with a poor prognosis – like IPF – survival is the most logical outcome to measure the efficacy of a given drug. However, such trial design is feasible only in diseases that are fairly common and have a short survival with no treatment already approved. When a mortality study is impracticable, an alternative approach involves the use of predictors of survival. There is a general agreement that the ideal primary endpoint should be reliable, reproducible, clinically meaningful, predictive of outcome, responsive to treatment effect, equally applicable to all patients, and easy to measure. However, none of the outcomes utilized over the last decade of clinical trials of IPF meets all these criteria. More attention is currently paid by physicians and regulators to endpoints that are meaningful to patients even on a short-term basis, including symptoms and quality of life measurements. In this chapter we carefully analyze the pros and cons of the outcomes most commonly used in pharmacological studies of IPF and suggest that the choice of the appropriate primary endpoint should balance scientific, statistical, and clinical rigor as well as clinical trial feasibility." @default.
- W2904237193 created "2018-12-22" @default.
- W2904237193 creator A5014703126 @default.
- W2904237193 creator A5030167238 @default.
- W2904237193 creator A5043303194 @default.
- W2904237193 date "2018-12-15" @default.
- W2904237193 modified "2023-09-23" @default.
- W2904237193 title "Clinical Trials in IPF: What Are the Best Endpoints?" @default.
- W2904237193 cites W1569431722 @default.
- W2904237193 cites W1580486037 @default.
- W2904237193 cites W1817992190 @default.
- W2904237193 cites W1893266514 @default.
- W2904237193 cites W1920916096 @default.
- W2904237193 cites W1970008616 @default.
- W2904237193 cites W1980903642 @default.
- W2904237193 cites W1984774336 @default.
- W2904237193 cites W1991660435 @default.
- W2904237193 cites W2000201583 @default.
- W2904237193 cites W2002587076 @default.
- W2904237193 cites W2011870650 @default.
- W2904237193 cites W2013155459 @default.
- W2904237193 cites W2035882325 @default.
- W2904237193 cites W2036041938 @default.
- W2904237193 cites W2039943389 @default.
- W2904237193 cites W2041557317 @default.
- W2904237193 cites W2042805913 @default.
- W2904237193 cites W2054919851 @default.
- W2904237193 cites W2055609841 @default.
- W2904237193 cites W2057292199 @default.
- W2904237193 cites W2057982527 @default.
- W2904237193 cites W2063869981 @default.
- W2904237193 cites W2066671076 @default.
- W2904237193 cites W2080677332 @default.
- W2904237193 cites W2083436606 @default.
- W2904237193 cites W2094232837 @default.
- W2904237193 cites W2095309945 @default.
- W2904237193 cites W2096828977 @default.
- W2904237193 cites W2098305693 @default.
- W2904237193 cites W2100059970 @default.
- W2904237193 cites W2100554882 @default.
- W2904237193 cites W2102969338 @default.
- W2904237193 cites W2108226118 @default.
- W2904237193 cites W2108280422 @default.
- W2904237193 cites W2109920600 @default.
- W2904237193 cites W2111088723 @default.
- W2904237193 cites W2111459732 @default.
- W2904237193 cites W2113575939 @default.
- W2904237193 cites W2114703873 @default.
- W2904237193 cites W2117488044 @default.
- W2904237193 cites W2117681009 @default.
- W2904237193 cites W2121910720 @default.
- W2904237193 cites W2125013258 @default.
- W2904237193 cites W2125322938 @default.
- W2904237193 cites W2131029325 @default.
- W2904237193 cites W2132639652 @default.
- W2904237193 cites W2133840159 @default.
- W2904237193 cites W2135178626 @default.
- W2904237193 cites W2138871107 @default.
- W2904237193 cites W2139890009 @default.
- W2904237193 cites W2140334695 @default.
- W2904237193 cites W2141623508 @default.
- W2904237193 cites W2142941142 @default.
- W2904237193 cites W2143487186 @default.
- W2904237193 cites W2144202648 @default.
- W2904237193 cites W2145491879 @default.
- W2904237193 cites W2146139012 @default.
- W2904237193 cites W2150824191 @default.
- W2904237193 cites W2152628336 @default.
- W2904237193 cites W2152974152 @default.
- W2904237193 cites W2157869208 @default.
- W2904237193 cites W2160906692 @default.
- W2904237193 cites W2161625871 @default.
- W2904237193 cites W2164641585 @default.
- W2904237193 cites W2167025947 @default.
- W2904237193 cites W2168666423 @default.
- W2904237193 cites W2168911526 @default.
- W2904237193 cites W2171738220 @default.
- W2904237193 cites W2174422634 @default.
- W2904237193 cites W2289682006 @default.
- W2904237193 cites W2315538569 @default.
- W2904237193 cites W2330561691 @default.
- W2904237193 cites W2335208833 @default.
- W2904237193 cites W2342846323 @default.
- W2904237193 cites W2404361839 @default.
- W2904237193 cites W2440054067 @default.
- W2904237193 cites W2512400480 @default.
- W2904237193 cites W2550523848 @default.
- W2904237193 cites W2560640434 @default.
- W2904237193 cites W2563246743 @default.
- W2904237193 cites W2567033981 @default.
- W2904237193 cites W2573619794 @default.
- W2904237193 cites W2590815617 @default.
- W2904237193 cites W2599075603 @default.
- W2904237193 cites W2604367936 @default.
- W2904237193 cites W2611007056 @default.
- W2904237193 cites W2614444402 @default.
- W2904237193 cites W2625334682 @default.
- W2904237193 cites W2744147503 @default.